128 related articles for article (PubMed ID: 18457325)
1. Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions.
Cooper WA; Kohonen-Corish MR; Zhuang L; McCaughan B; Kennedy C; Screaton G; Sutherland RL; Lee CS
Cancer; 2008 Jul; 113(1):135-42. PubMed ID: 18457325
[TBL] [Abstract][Full Text] [Related]
2. Expression of DR5 and c‑FLIP proteins as novel prognostic biomarkers for non‑small cell lung cancer patients treated with surgical resection and chemotherapy.
Zheng H; Zhang Y; Zhan Y; Liu S; Lu J; Wen Q; Fan S
Oncol Rep; 2019 Dec; 42(6):2363-2370. PubMed ID: 31638235
[TBL] [Abstract][Full Text] [Related]
3. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer.
Cooper WA; Kohonen-Corish MR; McCaughan B; Kennedy C; Sutherland RL; Lee CS
Histopathology; 2009 Jul; 55(1):28-36. PubMed ID: 19614764
[TBL] [Abstract][Full Text] [Related]
4. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
[TBL] [Abstract][Full Text] [Related]
5. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
Leithner K; Stacher E; Wurm R; Ploner F; Quehenberger F; Wohlkoenig C; Bálint Z; Polachova J; Olschewski A; Samonigg H; Popper HH; Olschewski H
Lung Cancer; 2009 Jul; 65(1):98-104. PubMed ID: 19081160
[TBL] [Abstract][Full Text] [Related]
6. Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer.
Koç Erbaşoğlu Ö; Horozoğlu C; Ercan Ş; Kara HV; Turna A; Farooqi AA; Yaylım İ
Libyan J Med; 2019 Dec; 14(1):1535746. PubMed ID: 30481147
[TBL] [Abstract][Full Text] [Related]
7. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
Odoux C; Albers A; Amoscato AA; Lotze MT; Wong MK
Int J Cancer; 2002 Feb; 97(4):458-65. PubMed ID: 11802207
[TBL] [Abstract][Full Text] [Related]
8. Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission.
Wu B; Xiong J; Zhou Y; Wu Y; Song Y; Wang N; Chen L; Zhang J
Arch Biochem Biophys; 2020 Oct; 692():108539. PubMed ID: 32777260
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
10. [Expression of alpha-tubulin and MDR1 and their correlation with the biological features of non-small cell lung carcinoma].
Chen QY; Jiang ZY; Wu LJ; Zhang BY; Lu GH; Zhou JY
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):278-82. PubMed ID: 20510079
[TBL] [Abstract][Full Text] [Related]
11. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
12. 5-allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells.
Xie ZH; Quan MF; Liu F; Cao JG; Zhang JS
BMC Cancer; 2011 Jul; 11():322. PubMed ID: 21801359
[TBL] [Abstract][Full Text] [Related]
13. N-Acetyl-Glucosamine Sensitizes Non-Small Cell Lung Cancer Cells to TRAIL-Induced Apoptosis by Activating Death Receptor 5.
Liang Y; Xu W; Liu S; Chi J; Zhang J; Sui A; Wang L; Liang Z; Li D; Chen Y; Niu H
Cell Physiol Biochem; 2018; 45(5):2054-2070. PubMed ID: 29533936
[TBL] [Abstract][Full Text] [Related]
14. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction.
Kim EO; Kang SE; Im CR; Lee JH; Ahn KS; Yang WM; Um JY; Lee SG; Yun M
Int J Oncol; 2016 May; 48(5):2205-12. PubMed ID: 26983803
[TBL] [Abstract][Full Text] [Related]
15. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions.
Zhuang H; Jiang W; Zhang X; Qiu F; Gan Z; Cheng W; Zhang J; Guan S; Tang B; Huang Q; Wu X; Huang X; Jiang W; Hu Q; Lu M; Hua ZC
J Mol Med (Berl); 2013 Feb; 91(2):219-35. PubMed ID: 22948392
[TBL] [Abstract][Full Text] [Related]
16. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.
Su L; Liu G; Hao X; Zhong N; Zhong D; Liu X; Singhal S
Eur J Cancer; 2011 Nov; 47(16):2471-8. PubMed ID: 21726997
[TBL] [Abstract][Full Text] [Related]
17. Expression of tumor necrosis factor-related apoptosis-inducing ligand death receptors DR4 and DR5 in human nonmelanoma skin cancer.
Omran OM; Ata HS
Am J Dermatopathol; 2014 Sep; 36(9):710-7. PubMed ID: 24212133
[TBL] [Abstract][Full Text] [Related]
18. Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer.
Zhao XD; Deng HB; Lu CL; Bao YX; Lu X; Deng LL
Neoplasma; 2017; 64(2):182-191. PubMed ID: 28043144
[TBL] [Abstract][Full Text] [Related]
19. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
Zhang Z; Ma J; Li N; Sun N; Wang C
Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
[TBL] [Abstract][Full Text] [Related]
20. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer.
Han JY; Hong EK; Choi BG; Park JN; Kim KW; Kang JH; Jin JY; Park SY; Hong YS; Lee KS
Med Oncol; 2003; 20(4):355-62. PubMed ID: 14716031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
